Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03332732 · ClinicalTrials.gov registry record · Phase 1
VNRX-5133 Drug-Drug Interaction in Healthy Adult Volunteers
A Phase 1 study, sponsored by Venatorx Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT03332732 is a Phase 1 study that has completed, run by Venatorx Pharmaceuticals. The registered enrollment target is 42 participants.
The verdict
NCT03332732, a Phase 1 study, has completed, sponsored by Venatorx Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
This is a 2-part, drug-drug interaction study to evaluate potential PK interactions after single doses in Part 1 and multiple doses in Part 2. In Part 1, subjects will receive single dose of 5 treatments in a cross-over design; in Part 2 subjects will receive treatment for 10 days.
Interventions
- DRUG Placebo
- DRUG Metronidazole
- DRUG VNRX-5133
- DRUG VNRX-5022
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2017-10-24 |
| Est. Completion | 2017-12-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03332732
The ClinicalTrials.gov registry entry for NCT03332732 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Venatorx Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT03332732 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03332732 about?
NCT03332732 is a clinical study titled "VNRX-5133 Drug-Drug Interaction in Healthy Adult Volunteers". This is a 2-part, drug-drug interaction study to evaluate potential PK interactions after single doses in Part 1 and multiple doses in Part 2. In Part 1, subjects will receive single dose of 5 treatments in a cross-over design; in Part 2 subjects will receive treatment for 10 days.
What is the current status of trial NCT03332732?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2017-10-24. Estimated completion is 2017-12-20.
What interventions are being tested in trial NCT03332732?
The interventions under investigation include: Placebo (DRUG), Metronidazole (DRUG), VNRX-5133 (DRUG), VNRX-5022 (DRUG).
Who is sponsoring clinical trial NCT03332732?
This trial is sponsored by Venatorx Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.